Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

The recommendation signals a long-awaited shift from a single imperfect metric toward a more personalised diagnosis ...

A major insurance company is no longer covering drugs like Zepbound prescribed solely for weight loss blaming exorbitant ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

But their exercise is so intense for their age that they are starting to injure themselves doing it. (My dad had a stress fracture that he almost didn't notice, and my mom broke her toe in dance class ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...